These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 30262843)

  • 1. Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development.
    Zaborsky N; Gassner FJ; Höpner JP; Schubert M; Hebenstreit D; Stark R; Asslaber D; Steiner M; Geisberger R; Greil R; Egle A
    Leukemia; 2019 Apr; 33(4):957-968. PubMed ID: 30262843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients.
    Öztürk S; Paul Y; Afzal S; Gil-Farina I; Jauch A; Bruch PM; Kalter V; Hanna B; Arseni L; Roessner PM; Schmidt M; Stilgenbauer S; Dietrich S; Lichter P; Zapatka M; Seiffert M
    Leukemia; 2022 Feb; 36(2):464-475. PubMed ID: 34417556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lessons learned from the Eµ-TCL1 mouse model of CLL.
    Floerchinger A; Seiffert M
    Semin Hematol; 2024 Jun; 61(3):194-200. PubMed ID: 38839457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia.
    Amin NA; Seymour E; Saiya-Cork K; Parkin B; Shedden K; Malek SN
    Clin Cancer Res; 2016 Sep; 22(17):4525-35. PubMed ID: 27060156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL.
    Hofbauer JP; Heyder C; Denk U; Kocher T; Holler C; Trapin D; Asslaber D; Tinhofer I; Greil R; Egle A
    Leukemia; 2011 Sep; 25(9):1452-8. PubMed ID: 21606964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice.
    Zanesi N; Aqeilan R; Drusco A; Kaou M; Sevignani C; Costinean S; Bortesi L; La Rocca G; Koldovsky P; Volinia S; Mancini R; Calin G; Scott CP; Pekarsky Y; Croce CM
    Cancer Res; 2006 Jan; 66(2):915-20. PubMed ID: 16424025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia.
    Bresin A; D'Abundo L; Narducci MG; Fiorenza MT; Croce CM; Negrini M; Russo G
    Cell Death Dis; 2016 Jan; 7(1):e2071. PubMed ID: 26821067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD5+CD23+ leukemic cell populations in TCL1 transgenic mice show significantly increased proliferation and Akt phosphorylation.
    Efanov A; Zanesi N; Nazaryan N; Santanam U; Palamarchuk A; Croce CM; Pekarsky Y
    Leukemia; 2010 May; 24(5):970-5. PubMed ID: 20357824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state.
    Herling M; Patel KA; Khalili J; Schlette E; Kobayashi R; Medeiros LJ; Jones D
    Leukemia; 2006 Feb; 20(2):280-5. PubMed ID: 16341048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic lymphocytic leukemia disease progression is accelerated by APRIL-TACI interaction in the TCL1 transgenic mouse model.
    Lascano V; Guadagnoli M; Schot JG; Luijks DM; Guikema JE; Cameron K; Hahne M; Pals S; Slinger E; Kipps TJ; van Oers MH; Eldering E; Medema JP; Kater AP
    Blood; 2013 Dec; 122(24):3960-3. PubMed ID: 24100449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic lymphocytic leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression.
    Enzler T; Kater AP; Zhang W; Widhopf GF; Chuang HY; Lee J; Avery E; Croce CM; Karin M; Kipps TJ
    Blood; 2009 Nov; 114(20):4469-76. PubMed ID: 19755673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eµ-TCL1 mouse model.
    Bresin A; Callegari E; D'Abundo L; Cattani C; Bassi C; Zagatti B; Narducci MG; Caprini E; Pekarsky Y; Croce CM; Sabbioni S; Russo G; Negrini M
    Oncotarget; 2015 Aug; 6(23):19807-18. PubMed ID: 26090867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL).
    Palamarchuk A; Yan PS; Zanesi N; Wang L; Rodrigues B; Murphy M; Balatti V; Bottoni A; Nazaryan N; Alder H; Rassenti L; Kipps TJ; Freitas M; Croce CM; Pekarsky Y
    Proc Natl Acad Sci U S A; 2012 Feb; 109(7):2555-60. PubMed ID: 22308499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression.
    Bichi R; Shinton SA; Martin ES; Koval A; Calin GA; Cesari R; Russo G; Hardy RR; Croce CM
    Proc Natl Acad Sci U S A; 2002 May; 99(10):6955-60. PubMed ID: 12011454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD4+ T cells sustain aggressive chronic lymphocytic leukemia in Eμ-TCL1 mice through a CD40L-independent mechanism.
    Grioni M; Brevi A; Cattaneo E; Rovida A; Bordini J; Bertilaccio MTS; Ponzoni M; Casorati G; Dellabona P; Ghia P; Bellone M; Calcinotto A
    Blood Adv; 2021 Jul; 5(14):2817-2828. PubMed ID: 34269799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Par-4 overexpression impedes leukemogenesis in the Eµ-TCL1 leukemia model through downregulation of NF-κB signaling.
    Greene JT; Mani R; Ramaswamy R; Frissora F; Yano M; Zapolnik K; Harrington B; Wasmuth R; Tran M; Mo X; McKenna M; Rangnekar VM; Byrd JC; Bondada S; Muthusamy N
    Blood Adv; 2019 Apr; 3(8):1255-1266. PubMed ID: 30987970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model.
    Motiwala T; Kutay H; Zanesi N; Frissora FW; Mo X; Muthusamy N; Jacob ST
    Leukemia; 2015 Jun; 29(6):1350-9. PubMed ID: 25482129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181.
    Pekarsky Y; Santanam U; Cimmino A; Palamarchuk A; Efanov A; Maximov V; Volinia S; Alder H; Liu CG; Rassenti L; Calin GA; Hagan JP; Kipps T; Croce CM
    Cancer Res; 2006 Dec; 66(24):11590-3. PubMed ID: 17178851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of NFAT2 expression results in the acceleration of clonal evolution in chronic lymphocytic leukemia.
    Müller DJ; Wirths S; Fuchs AR; Märklin M; Heitmann JS; Sturm M; Haap M; Kirschniak A; Sasaki Y; Kanz L; Kopp HG; Müller MR
    J Leukoc Biol; 2019 Mar; 105(3):531-538. PubMed ID: 30556925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accelerated progression of chronic lymphocytic leukemia in Eμ-TCL1 mice expressing catalytically inactive RAG1.
    Nganga VK; Palmer VL; Naushad H; Kassmeier MD; Anderson DK; Perry GA; Schabla NM; Swanson PC
    Blood; 2013 May; 121(19):3855-66, S1-16. PubMed ID: 23502221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.